BrainStorm Cell Therapeutics Announces Publication of NurOwn® ALS Phase 2 Randomized Clinical Trial Data in Neurology
November 20, 2019 07:00 ET
|
BrainStorm Cell Therapeutics Inc.
A single transplantation of MSC-NTF cells (NurOwn®) in ALS clinical trial participants met the primary safety endpoint and demonstrated promising stabilization of ALS disease progression of up to...
BrainStorm Cell Therapeutics Announces Research Grant Award From the National Multiple Sclerosis Society
November 14, 2019 07:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that...
BrainStorm Announces Financial Results for the Third Quarter of 2019 and Provides a Corporate Update
November 14, 2019 06:00 ET
|
BrainStorm Cell Therapeutics Inc.
Conference Call and Webcast Today at 8:00 a.m. Eastern Time Highlights Include: ALS Phase 3 Clinical Trial Fully Enrolled, Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial...
BrainStorm Announces Grant of a New Japanese Patent for NurOwn®
November 13, 2019 05:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that...
BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting
November 12, 2019 01:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...
BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Comprehensive Corporate Update
November 05, 2019 06:15 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...
NurOwn® Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial Continue
October 28, 2019 07:45 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...
BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
October 25, 2019 01:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
BrainStorm Cell Therapeutics’ President and CEO to be Featured as Keynote Speaker at Cell Series UK 2019
October 24, 2019 08:45 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
BrainStorm Cell Therapeutics Presentations at Neuromuscular Drug Development Summit
October 23, 2019 01:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Oct. 23, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...